A double blind randomised placebo controlled parallel trial of the effect of fosinopril, an angiotensin converting enzyme inhibitor, on the quadriceps muscle in 80 COPD patients who have quadriceps weakness. Patients will have a baseline assessment including measures of quadriceps strength and endurance and a quadriceps biopsy. Patients with weakness will be randomised to ACE inhibitor or placebo and re-assessed after three months of treatment. The investigators aim to show that ACE-inhibition will alter the IGF-1/AKT/FoXO/atrogene pathways involved in muscle wasting in COPD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
80
10mg od
placebo
Royal Brompton Hospital
London, United Kingdom
Changes in phosphorylation of components of the atrogene pathway
Time frame: 3 months
Quadriceps endurance assessed non-volitionally
Time frame: 3 months
Effect of ACE-I on quadriceps maximum voluntary contraction force
Time frame: 3 months
Effect of ACE-I on quadriceps bulk (cross-sectional area)
Time frame: 3 months
Effect of ACE-I on systemic inflammation and serum IGF-1
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.